Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CanSino Biologics Inc. (CanSinoBIO) is a biopharmaceutical company that researches, develops, manufactures, and commercializes vaccine products for the prevention and treatment of infectious diseases. The company offers products such as group acyw135 meningococcal conjugate vaccine, group a and group c meningococcal conjugate vaccine, recombinant covid-19 vaccine, and recombinant covid-19 vaccine products. CanSinoBIO's technology platform includes adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, and formulation and drug delivery technology. CanSino Biologics is headquartered in Tianjin, China.
Headquarters
China
Address
Biomedical Park, 185 South Avenue, Tianjin, 300457
Website
www.cansinotech.com
Telephone
86 400 9222099
No of Employees
1,134
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
6185 (HKG)
Revenue (2024)
$147.4M
28.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
107.4%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
105.7%
(2024 vs 2023)
* As of and is in US$
CanSino Biologics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Recombinant COVID-19 Vaccine | Service: | Tripecia |
| Recombinant Novel Coronavirus Vaccine | Contractual Development and Manufacturing Services | Menhycia |
| Group A and Group C Meningococcal Conjugate Vaccine | Medical Research and Experimental Development Services | iPneucia |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company received acceptance from the National Medical Products Administration of China for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed. |
| 2026 | Plans/Strategy | In July, the company entered into a letter of intent with AGP Limited in Pakistan to analyze potential opportunities related to CanSinoBIO's 13-valent pneumococcal conjugate vaccine in Pakistan. |
| 2026 | Regulatory Approval | In June, the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) secured the drug registration certificate granted by the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) of Argentina. |
Competitor Comparison
| Key Parameters | CanSino Biologics Inc | Sino Biopharmaceutical Ltd | Chongqing Zhifei Biological Products Co Ltd | Beijing Tiantan Biological Products Co Ltd | Sinovac Biotech Ltd |
|---|---|---|---|---|---|
| Headquarters | China | Hong Kong | China | China | China |
| City | Tianjin | Hong Kong City | Chongqing | Beijing | Beijing |
| State/Province | Tianjin | - | Chongqing | Beijing | Beijing |
| No. of Employees | 1,134 | 24,379 | 6,292 | 5,205 | 3,037 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xuefeng Yu, Ph.D | Chief Executive Officer; General Manager; Chairman | Executive Board | 2009 | 61 |
| Shou Bai Chao, Ph.D. | Deputy General Manager; Director; Chief Operating Officer | Executive Board | 2018 | 62 |
| Jing Wang | Director; Chief Commercial Officer; Deputy General Manager | Executive Board | 2021 | 45 |
| Ming King Chiu | Joint Secretary | Senior Management | - | - |
| Jin CUI | Joint Secretary | Senior Management | 2021 | 39 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer